Substituted indolinones with kinase inhibitory activity
    1.
    发明授权
    Substituted indolinones with kinase inhibitory activity 有权
    具有激酶抑制活性的取代的吲哚啉酮

    公开(公告)号:US06545035B1

    公开(公告)日:2003-04-08

    申请号:US09969912

    申请日:2001-10-03

    IPC分类号: A61K314035

    CPC分类号: C07D209/30 C07D209/34

    摘要: Substituted indolinones of general formula having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. Exemplary compounds are: 3-Z-[1-(4-(N-Benzyl-N-methyl-aminomethyl)-phenylamino)-1-methyl-methylene]-5-amido-2-indolinone and 3-Z-[1-(4-(2,3,4,5-Tetrahydro-benzo(d)azepin-3-yl-methyl)-phenylamino)-1-methyl-methylene]-5-amido-2-indolinone.

    摘要翻译: 通用结构式取代的吲哚酮对各种激酶和cyclin / CDK复合物的影响以及各种肿瘤细胞的增殖。 示例性化合物是:3-Z- [1-(4-(N-苄基-N-甲基 - 氨基甲基) - 苯基氨基)-1-甲基 - 亚甲基] -5-酰氨基-2-二氢吲哚酮和3-Z- [1- (4-(2,3,4,5-四氢 - 苯并(d)氮杂-3-基 - 甲基) - 苯基氨基)-1-甲基 - 亚甲基] -5-酰氨基-2-二氢吲哚酮。

    Substituted indolinones with kinase inhibitory activity
    2.
    发明授权
    Substituted indolinones with kinase inhibitory activity 有权
    具有激酶抑制活性的取代的吲哚啉酮

    公开(公告)号:US06319918B1

    公开(公告)日:2001-11-20

    申请号:US09323499

    申请日:1999-06-01

    IPC分类号: A61K3155

    CPC分类号: C07D209/30 C07D209/34

    摘要: Substituted indolinones of general formula having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. Exemplary compounds are: 3-Z-[1-(4-(N-Benzyl-N-methyl-aminomethyl)-phenylamino)-1-methyl-methylene]-5-amido-2-indolinone and 3-Z-[1-(4-(2,3,4,5-Tetrahydro-benzo(d)azepin-3-yl-methyl)-phenylamino)-1-methyl-methylene]-5-amido-2-indolinone.

    摘要翻译: 通用结构式取代的吲哚酮对各种激酶和cyclin / CDK复合物的影响以及各种肿瘤细胞的增殖。 示例性化合物是:3-Z- [1-(4-(N-苄基-N-甲基 - 氨基甲基) - 苯基氨基)-1-甲基 - 亚甲基] -5-酰氨基-2-二氢吲哚酮和3-Z- [1- (4-(2,3,4,5-四氢 - 苯并(d)氮杂-3-基 - 甲基) - 苯基氨基)-1-甲基 - 亚甲基] -5-酰氨基-2-二氢吲哚酮。

    Indolinones having kinase inhibitory activity
    3.
    发明授权
    Indolinones having kinase inhibitory activity 有权
    具有激酶抑制活性的吲哚酮

    公开(公告)号:US06169106A

    公开(公告)日:2001-01-02

    申请号:US09286983

    申请日:1999-04-06

    IPC分类号: A61K31404

    CPC分类号: C07D209/04

    摘要: The present invention relates to substituted indolinones of general formula wherein R1 to R5, and X are defined as in claim 1, the isomers thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibitory effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these (compounds, their use and processes for preparing them.

    摘要翻译: 本发明涉及R1至R5的通式化合物的取代的吲哚啉酮,X如权利要求1所定义,其定义如下:异构体及其盐,特别是其生理上可接受的盐,其具有有价值的药理学性质,特别是对各种激酶的抑制作用, 循环/ CDK复合物和各种肿瘤细胞的增殖,含有这些(化合物,其用途和制备方法)的药物组合物。

    Morpholines and morpholine-N-oxides and pharmaceutical compositions
containing these compounds
    9.
    发明授权
    Morpholines and morpholine-N-oxides and pharmaceutical compositions containing these compounds 失效
    吗啉和吗啉-N-氧化物和含有这些化合物的药物组合物

    公开(公告)号:US5026702A

    公开(公告)日:1991-06-25

    申请号:US327665

    申请日:1989-03-23

    IPC分类号: C07D413/04 H04L1/22

    CPC分类号: C07D413/04

    摘要: The invention relates to new morpholines and morpholine-N-oxides of formula ##STR1## wherein the substituents are defined hereunder, which compounds have valuable pharmacological properties, namely an effect on the metabolism, preferably the effect of lowering blood sugar and reducing body fat, and the effect of lowering the atherogenic .beta.-lipoproteins VLDL and LDL, and a performance enhancing effect in animals.

    摘要翻译: 本发明涉及式(I)的新的吗啉和吗啉-N-氧化物,其中取代基定义在下文中,哪些化合物具有有价值的药理学性质,即对代谢的影响,优选降低血糖的作用和降低 人体脂肪,以及降低致动脉粥样硬化的β-脂蛋白VLDL和LDL的作用,以及在动物中的表现增强作用。

    Fused-ring amino-pyrazines as bradycardiac agents
    10.
    发明授权
    Fused-ring amino-pyrazines as bradycardiac agents 失效
    稠环氨基吡嗪作为心动过缓剂

    公开(公告)号:US4409220A

    公开(公告)日:1983-10-11

    申请号:US297024

    申请日:1981-08-27

    CPC分类号: C07D471/04 C07D487/04

    摘要: Compounds of the formula ##STR1## wherein A and B, which may be the same or different, each represent methylene, (alkyl of 1 to 3 carbon atoms)-methylene, ethylene or (alkyl of 1 to 3 carbon atoms)-ethylene;R.sub.1 is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 7 carbon atoms, alkenyl of 3 to 6 carbon atoms, phenyl-(alkyl of 1 to 3 carbon atoms), halophenyl-(alkyl of 1 to 3 carbon atoms), alkanoyl of 1 to 3 carbon atoms, phenyl-(alkanoyl of 1 to 3 carbon atoms), halophenyl-(alkanoyl of 1 to 3 carbon atoms), alkoxycarbonyl of 2 to 4 carbon atoms, aralkoxycarbonyl of 8 to 10 carbon atoms or phenyl;one of R.sub.2 and R.sub.3 is amino and the other is hydrogen, chlorine, bromine, alkyl of 1 to 3 carbon atoms, alkoxy of 1 to 3 carbon atoms, alkoxycarbonyl of 2 to 4 carbon atoms, phenyl or halophenyl;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as bradycardiacs.

    摘要翻译: 其中A和B可以相同或不同,各自表示亚甲基,(1至3个碳原子的烷基) - 亚甲基,亚乙基或(1至3个碳原子的烷基) - 亚乙基; R 1是氢,1至6个碳原子的烷基,3至7个碳原子的环烷基,3至6个碳原子的烯基,苯基 - (1至3个碳原子的烷基),卤代苯基 - (1至3个碳原子的烷基 ),1〜3个碳原子的烷酰基,1〜3个碳原子的苯基 - (烷酰基),1〜3个碳原子的卤代苯基 - (烷酰基),2〜4个碳原子的烷氧基羰基,8〜10个碳原子的芳烷氧羰基, 苯基; R2和R3中的一个是氨基,另一个是氢,氯,溴,1至3个碳原子的烷基,1至3个碳原子的烷氧基,2至4个碳原子的烷氧基羰基,苯基或卤代苯基; 和无毒的,药学上可接受的酸加成盐。 化合物及其盐可用作心动过缓。